Schizophrenia negative symptoms are relatively stable in the first year for most patients after they begin antipsychotic medication but research suggests around a quarter will experience exacerbation or relapse.
Study findings provide support for psychotic experiences being an early marker of increased risk of psychosis transition and an important intermediary phenotype in transdiagnostic research on psychosis.
The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found.
Patients at ultra-high-risk for psychosis frequently have nonpsychotic disorders and often continue to experience attenuated psychotic symptoms, even if they do not transition to clinical psychosis, a study shows.
The positive effects of omega-3 supplementation seen in patients at high risk of psychosis in a previous randomised, controlled trial may be sustained, the investigators reported at the International Early Psychosis Conference in Tokyo, Japan.
The association between suicidal ideation and later suicide is much stronger in patients with schizophrenia spectrum psychosis than in those with mood disorders, show results of a systematic meta-analysis.
Atypical antipsychotic drugs benefit patients with acute schizophrenia across the full spectrum of symptom severity, as well as highly symptomatic patients with predominantly negative symptoms, suggests a meta-analysis published in JAMA Psychiatry.